Will Lineage Cell Therapeutics stock go up?

According to Danelfin AI, Lineage Cell Therapeutics has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (59.01%) is +8.20% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Lineage Cell Therapeutics stock?

The Lineage Cell Therapeutics target price is $5.63 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Lineage Cell Therapeutics stock right now?

Lineage Cell Therapeutics has today a Buy rating (AI Score 7/10), according to Danelfin AI. Its probability of beating the market in 3 months (59.01%) is +8.20% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Lineage Cell Therapeutics stock is a good buy .

Is Lineage Cell Therapeutics undervalued right now?

Based on analysts, the average price target upside for Lineage Cell Therapeutics is +329.69% (1Y). According to Danelfin AI, Lineage Cell Therapeutics has today an AI Score of 7/10 (Buy Rating).

What was the price range of Lineage Cell Therapeutics stock over the past 12 months?

The Lineage Cell Therapeutics stock price range over the past 12 months has been $0.9 - $1.96.

What is going on with Lineage Cell Therapeutics stock in the last 3 months?

The Lineage Cell Therapeutics stock performance in the last quarter has been -17.08%.

Does Lineage Cell Therapeutics offer dividend payments?

No, Lineage Cell Therapeutics does not currently pay dividends.

What is the current market capitalization of Lineage Cell Therapeutics?

Lineage Cell Therapeutics's market cap is $324.09M, as of 2026-07-02 08:00.

When is the next LCTX earnings report date?

LCTX will publish its next earnings report on 2026-05-12.

Lineage Cell Therapeutics Inc (LCTX) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

LCTX AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+5.32%
Direction and strength of recent price movements
Valuation+1.71%
How the stock is priced relative to its fundamentals
Volatility+1.13%
How much the stock price tends to fluctuate
Earnings Quality+0.93%
Stability and reliability of reported earnings

Profitability-0.82%
Profitability and operating efficiency metrics
Sentiment-0.08%
How analysts and the market view the stock

LCTX probability advantage of beating the market (3M):

+8.20%

Technical

Lineage Cell Therapeutics (LCTX) has a Technical Score of 8/10 because, according to only technical analysis, it has a probability advantage of +6.21% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.64%) and the probability of LCTX (56.85%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.64%
LCTX probability advantage of beating the market (only technical, 3M)+6.21%
LCTX probability of beating the market (3M)56.85%

LCTX probability advantage of beating the market (only technical, 3M): +6.21%

The AI-powered technical analysis of Lineage Cell Therapeutics (LCTX) is only based on the 28 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of LCTX:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	+2.14%
Technical	Upgrade to Pro to unlock	+0.94%
Technical	Upgrade to Pro to unlock	+0.93%
Technical	Upgrade to Pro to unlock	-0.79%
Technical	Upgrade to Pro to unlock	-0.72%
Technical	Upgrade to Pro to unlock	-0.67%
Technical	Upgrade to Pro to unlock	+0.66%
Technical	Upgrade to Pro to unlock	+0.62%
Technical	Upgrade to Pro to unlock	+0.60%
Technical	Upgrade to Pro to unlock	+0.59%
Technical	Upgrade to Pro to unlock	+0.46%
Technical	Upgrade to Pro to unlock	+0.44%
Technical	Upgrade to Pro to unlock	+0.38%
Technical	Upgrade to Pro to unlock	+0.33%
Technical	Upgrade to Pro to unlock	+0.32%

Rest of Alpha Signals: -0.32%

LCTX probability advantage of beating the market (only technical, 3M)Total:+6.21%
LCTX Technical Score

Significant changes Vs previous day

LCTX Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$1.31
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 7/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 7/10

LCTX Proven Buy Signal & Price Forecast

This is the price chart for LCTX from January 2, 2026 until today. The chart indicates, in green, the 54 days when the stock received a Buy/Strong Buy rating (buy signals, AI Score 7 to 10).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Buy signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Buy signals

Forecast:

1 Month
3 Months
6 Months
1 Year

LCTX Average Past Performance & Win Rate

Three months after its 629 Buy signals since July 2026, LCTX had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

629 Past LCTX Buy Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+5.19%
Average Alpha				-10.82%
Win Rate (% Positive Perf.)				27.84%
% Positive Alpha				20.98%

LCTX Frequently Asked Questions

Will Lineage Cell Therapeutics stock go up?
According to Danelfin AI, Lineage Cell Therapeutics has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (59.01%) is +8.20% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Lineage Cell Therapeutics stock?
Is it a good time to buy, sell, or hold Lineage Cell Therapeutics stock right now?
Is Lineage Cell Therapeutics undervalued right now?
What was the price range of Lineage Cell Therapeutics stock over the past 12 months?
What is going on with Lineage Cell Therapeutics stock in the last 3 months?
Does Lineage Cell Therapeutics offer dividend payments?
What is the current market capitalization of Lineage Cell Therapeutics?
When is the next LCTX earnings report date?

Lineage Cell Therapeutics Inc Company Profile

Lineage Cell Therapeutics, Inc. is a clinical-stage biotech firm that pioneers robust cell therapies targeting unfulfilled medical needs on both national and international stages. They are behind OpRegen, an innovative allogeneic retinal pigment epithelium cell replacement therapy currently undergoing Phase 2a clinical trials as a potential treatment for dry age-related macular degeneration.

They also helm OPC1, an allogeneic oligodendrocyte progenitor cell therapy making strides in the Phase 1/2a multicenter clinical trial stage, designed as a novel solution for cervical spinal cord injuries. Meanwhile, their VAC remains in the Phase I clinical trial stage: this groundbreaking allogenic cancer immunotherapy tool focuses on antigen-presenting dendritic cells to combat non-small cell lung cancer.

In the preclinical development phase are two other game-changing solutions: ANP1 - an allogeneic auditory neuron progenitor cell transplant aiming to treat severe hearing loss; and PNC1 - an allogeneic photoreceptor cell transplant developed to replace vision lost due to photoreceptor dysfunction or damage.

Furthermore, apart from these specialized treatments Lineage Cell Therapeutics extends its research and development capacities into devising effective products for retinal diseases, neurological disorders and oncology. They have also partnered with Immunomic Therapeutics, Inc., focusing on treating glioblastoma multiforme.

Born as BioTime, Inc., the company underwent a strategic name change to Lineage Cell Therapeutics, Inc. in August 2019 to better align with its mission. First incorporated back in 1990,the company has since established its headquarters in Carlsbad, California.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:2173 Salk Avenue, Suite 200, Carlsbad
Employees:75
Website:lineagecell.com

Pros

Proprietary allogeneic cell therapy platforms

High switching costs for adopted cell therapies

Addressing unmet medical needs in degenerative diseases

Extensive intellectual property protection potential

Scalability advantage of allogeneic manufacturing

Cons

Intense regulatory pathway for cell therapies

High capital expenditure for clinical development

Inherent clinical trial failure risk

Reimbursement challenges for novel therapeutic modalities

Competition from alternative therapeutic approaches

Company	AI Score	Compare
IPSCCentury Therapeutics Inc
ALLOAllogene Therapeutics Inc
IRDOpus Genetics Inc
PMCBPharmaCyte Biotech Inc
CELUCelularity Inc

Company	AI Score	Compare
IPSCCentury Therapeutics Inc
ALLOAllogene Therapeutics Inc
IRDOpus Genetics Inc
PMCBPharmaCyte Biotech Inc
CELUCelularity Inc

LCTX Stock AI Analysis